MJA
MJA InSight
MJA Careers
Editorials

Translating advances in schizophrenia treatment: a glass ceiling

Patrick D McGorry
Med J Aust 2003; 178 (9): 425-426.

Reforms to the management of schizophrenia in Australia have stalled

Patrick D McGorry, MD FRANZCP, Professor; and Director, Orygen Youth Health and Orygen Research Centre
Department of Psychiatry, University of Melbourne, Parkville, VIC.
Article References: 
Reference Text: 
Burdekin B, Guilfoyle M, Hall D. Human rights and mental illness. Report of the National Inquiry into the Human Rights of People with Mental Illness. Canberra: AGPS, 1993.
Reference Order: 
1
PubMed ID: 
Reference Text: 
Pilling S, Bebbington P, Kuipers E, et al. Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy. Psychol Med 2002; 32: 763-782.
Reference Order: 
2
PubMed ID: 
12171372
Reference Text: 
Edwards J, McGorry PD, editors. Implementing early intervention in psychosis: a guide to establishing early psychosis services. London: Dunitz, 2002.
Reference Order: 
3
PubMed ID: 
Reference Text: 
Jablensky A, McGrath J, Herrman H, et al. People living with psychotic illness: an Australian Study 1997–98. Canberra: Commonwealth Department of Health and Aged Care, 1999.
Reference Order: 
4
PubMed ID: 
Reference Text: 
McGorry PD, Yung AR. Early intervention in psychosis: an overdue reform. An introduction to the Early Psychosis Symposium. Aust N Z J Psychiatry Supplement 2003. In press.
Reference Order: 
5
PubMed ID: 
Reference Text: 
Auditor General Victoria. Mental health services for people in crisis. Melbourne: Government Printer for the State of Victoria, 2002.
Reference Order: 
6
PubMed ID: 
Reference Text: 
McGorry PD, Killackey E, Lambert T, Lambert M. Summary Australian and New Zealand College of Psychiatrists Guidelines for the treatment of schizophrenia 2003. Australas Psychiatry 2003. In press.
Reference Order: 
7
PubMed ID: 
Reference Text: 
Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. London: National Institute for Clinical Health Excellence, 2002.
Reference Order: 
8
PubMed ID: 
Reference Text: 
Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371-1376.
Reference Order: 
9
PubMed ID: 
11099280
Reference Text: 
Czernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346: 16-22.
Reference Order: 
10
PubMed ID: 
11777998
Reference Text: 
Meltzer HY, Alphs L, Green AI, et al, for the InterSePT Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60: 82-91.
Reference Order: 
11
PubMed ID: 
12511175
Reference Text: 
Morgan V, Castle D, Jablensky A. The use of psychopharmacological and other treatments by persons with psychosis. Canberra: Commonwealth Department of Health and Ageing, 2002.
Reference Order: 
12
PubMed ID: 
Reference Text: 
Andrews G, Sanderson K, Corry J, et al. The cost effectiveness of current and optimal treatment for schizophrenia: evidence based medicine is affordable. Br J Psychiatry 2003. In press.
Reference Order: 
13
PubMed ID: 
Reference Text: 
SANE Australia. Schizophrenia: costs. An analysis of the burden of schizophrenia and related suicide in Australia. Access Economics Report for SANE Australia, 2002. Available at: http://www.sane.org/szcosts.pdf (accessed Apr 2003).
Reference Order: 
14
PubMed ID: 
Reference Text: 
Sartorius N. Stigma: what can psychiatrists do about it? Lancet 1998; 352: 1058-1059.
Reference Order: 
15
PubMed ID: 
9759771

The full contents of this page are only available to subscribers.